Business Context and Reporting Period
Company: Evotec SE (Evotec AG)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Third Quarter and Nine Months ended September 30, 2009
Filing Date: November 12, 2009
Evotec is a provider of drug discovery and development services focusing on small molecule drugs. The filing reports on the execution of the "Evotec 2012 - Action Plan to Focus and Grow," which involved significant restructuring, the closure of US operations, and a strategic shift to concentrate trading on the German TecDAX platform. On November 10, 2009, the company announced plans to voluntarily delist its American Depositary Shares (ADS) from NASDAQ.
Key Financial Metrics
| Metric | 9 Months Ended Sept 30, 2009 | 9 Months Ended Sept 30, 2008 | Q3 2009 | Q3 2008 |
|---|---|---|---|---|
| Revenue | EUR 29.1 million | EUR 25.2 million | EUR 10.4 million | EUR 10.7 million |
| Gross Margin | 38.3% | 38.0% | 39.4% | 55.6% |
| Operating Loss | EUR 32.9 million | EUR 35.2 million | EUR 3.8 million | EUR 8.3 million |
| Operating Loss (Excl. Exceptional Items) | EUR 21.6 million | EUR 35.1 million | N/A | N/A |
| Net Loss | EUR 34.1 million | EUR 29.0 million | EUR 3.7 million | EUR 3.1 million |
| Liquidity (Cash & Equivalents) | EUR 64.0 million (as of Sept 30) | EUR 92.4 million (as of Dec 31, 2008) | N/A | N/A |
| Operating Cash Flow | (EUR 23.6 million) | (EUR 32.7 million) | N/A | N/A |
Debt and Capital Structure: The company repaid EUR 2.5 million in bank loans during the period. Total stockholders' equity was EUR 121.4 million as of September 30, 2009. The equity ratio remained high at 78%.
Material Changes vs. Prior Period
- Revenue Growth: Nine-month revenue increased 16% year-over-year, driven by strong discovery alliance performance and upfront payments from Roche (EUR 2.0 million) and license/royalty income.
- Cost Reductions: Restructuring measures resulted in a 66% decrease in Q3 R&D expenses (to EUR 3.2 million) and a 13% decrease in Q3 SG&A expenses. Total restructuring expenses for the nine months were EUR 4.7 million.
- Impairment Charges: A one-time impairment charge of EUR 6.6 million was recorded in Q1 2009 related to the delay of the VR1 antagonist collaboration with Pfizer. This charge did not occur in the prior year.
- Acquisitions: Completed the acquisition of Research Support International Private Limited (RSIPL) in India for EUR 2.4 million on August 31, 2009, adding 154 employees.
- Operational Shift: Closed the US facility in South San Francisco (Renovis) to concentrate operations in Europe.
Guidance, Outlook, and Risks
Management Commentary and Guidance
- 2009 Revenue Guidance: Confirmed revenue guidance of greater than EUR 40 million for the full year 2009 (increased from a previous guidance of >EUR 35 million).
- Liquidity Guidance: Confirmed year-end liquidity guidance of greater than EUR 65 million. Current liquidity stands at EUR 64.0 million.
- Cash Flow: Management expects the fourth quarter of 2009 to be cash flow positive, driven by revenue contributions including a EUR 2.5 million milestone payment from Boehringer Ingelheim.
- Strategic Partnerships: Announced a four-year extension of the discovery collaboration with Boehringer Ingelheim (Nov 9, 2009) and a new program with Ono Pharmaceutical (Oct 2009).
Risks and Contingencies
- Clinical Delays: The Phase II study for EVT 101 (treatment-resistant depression) is now expected to start in early 2010 rather than late 2009 due to FDA feedback on toxicology and a more complex study design.
- Delisting Risks: Risks associated with the voluntary delisting from NASDAQ and deregistration with the SEC, including potential impacts on shareholder liquidity and market visibility.
- Restructuring Execution: Risk that cost containment measures may not reduce cash burn within the expected timeframe.
- Regulatory and Development Risks: Standard risks regarding clinical trial failures, regulatory approvals (FDA), and the ability to secure future partnerships.
Investor Verification Checklist
- Liquidity Runway: Verify the company's ability to maintain liquidity above EUR 65 million by year-end, specifically monitoring the timing of the Boehringer Ingelheim milestone payment.
- Delisting Impact: Assess the impact of the NASDAQ delisting (effective Nov 30, 2009) on share trading volume and liquidity on the TecDAX platform.
- Clinical Timeline: Monitor the start date of the EVT 101 Phase II trial (now expected early 2010) and the results of the EVT 103 Phase I study (data expected early 2010).
- Restructuring Savings: Confirm that the 66% reduction in Q3 R&D expenses is sustainable and not a one-time anomaly.
- Partnership Milestones: Track the achievement of pre-clinical milestones with Boehringer Ingelheim and Ono Pharmaceutical to ensure expected revenue recognition.